ArticleMicrobial genomics2018
Out of Asia: the independent rise and global spread of fluoroquinolone-resistant Shigella.
Article in Microbial genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis.Clinical and translational science · 2026Trial
- Global distribution and genomic characteristics ofInfectious medicine · 2026Article
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Multidrug-resistant Shigella flexneri outbreak affecting humans and non-human primates in New Mexico, USA.Nature communications · 2025Article
- Article
- Trends in shigellosis notifications in England, January 2016 to March 2023.Epidemiology and infection · 2024Article
- Article
- Epidemiological analysis and prevention strategies in response to a shigellosis cluster outbreak: a retrospective case series in an alternative school in the Republic of Korea, 2023.Osong public health and research perspectives · 2024Article
- Age-dependent acquisition of IgG antibodies toFrontiers in immunology · 2024Article
- The genomic epidemiology of shigellosis in South Africa.Nature communications · 2023Article
- Burden of diarrhea and antibiotic use among children in low-resource settings preventable by Shigella vaccination: A simulation study.PLoS medicine · 2023Article
- [Shigellosis attended in the emergency department of a regional hospital in southeastern Spain: from their presence to multiresistance].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Prevalence of Multidrug-Resistant and Extended-Spectrum Beta-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2022Review
- Article
- Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs.Nature microbiology · 2022Article
- Early genetic diagnosis of clarithromycin resistance inWorld journal of gastroenterology · 2021Article
- Effects of Three-Layer Encapsulated Tea Tree Oil on Growth Performance, Antioxidant Capacity, and Intestinal Microbiota of Weaned Pigs.Frontiers in veterinary science · 2021Article
- Shigella sonnei: virulence and antibiotic resistance.Archives of microbiology · 2021Review
- Dissecting the molecular evolution of fluoroquinolone-resistant Shigella sonnei.Nature communications · 2019Article
- A requirement for septins and the autophagy receptor p62 in the proliferation of intracellular Shigella.Cytoskeleton (Hoboken, N.J.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Shigella are ranked among the most prevalent aetiologies of diarrhoeal disease worldwide, disproportionately affecting young children in developing countries and high-risk communities in developed settings. Antimicrobial treatment, most commonly with fluoroquinolones, is currently recommended for Shigella infections to alleviate symptoms and control disease transmission. Resistance to fluoroquinolones has emerged in differing Shigella species (S. dysenteriae, flexneri and sonnei) since the turn of the 21st century, originating in endemic areas, and latterly spreading into non-endemic regions. Despite occurring independently, the emergence of fluoroquinolone resistance in these different Shigella species shares striking similarities regarding their epidemiology and resistance mechanisms. Here, we review and discuss the current epidemiology of fluoroquinolone-resistant Shigella species, particularly in the light of recent genomic insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.